1. Home
  2. PRTA

PRTA

Prothena Corporation plc

Logo Prothena Corporation plc

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-17-2024 12:12pm EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Founded: 2012 Country:
Ireland
Ireland
Employees: N/A City: DUBLIN 2
Market Cap: 1.2B IPO Year: N/A
Target Price: $67.14 AVG Volume (30 days): 678.5K
Analyst Decision: Buy Number of Analysts: 8
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.76 EPS Growth: N/A
52 Week Low/High: $21.90 - $79.65 Next Earning Date: 05-02-2024
Revenue: $91,370,000 Revenue Growth: 69.50%
Revenue Growth (this year): -86.58% Revenue Growth (next year): 702.03%

Share on Social Networks: